Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ruppert

Showing results (161-170 of 188) with videos related to

Pageof 19
Sort By:
Leukemia & Lymphoma|February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.
Journal of Geriatric Oncology|June 17, 2023
Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemiaP Connor Johnson, Jennifer A Woyach, Angela Ulrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseThomas S Lin, Amy S Ruppert, Amy J Johnson, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Nature Genetics|January 19, 2016
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemiaChristopher C Oakes, Marc Seifert, Yassen Assenov, et al.
Blood|March 23, 2021
Phase 2 study of ibrutinib in classic and variant hairy cell leukemiaKerry A Rogers, Leslie A Andritsos, Lai Wei, et al.
Blood|May 29, 2014
Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemiaRainer Claus, David M Lucas, Amy S Ruppert, et al.
Blood Advances|January 4, 2018
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinibCecelia R Miller, Amy S Ruppert, Nyla A Heerema, et al.
Nature Communications|November 4, 2021
Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemiaJanek S Walker, Zachary A Hing, Steven Sher, et al.
Pageof 19

Showing results (161-170 of 188) with videos related to

Sort By:
Pageof 19
Leukemia & Lymphoma|February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.
Journal of Geriatric Oncology|June 17, 2023
Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemiaP Connor Johnson, Jennifer A Woyach, Angela Ulrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseThomas S Lin, Amy S Ruppert, Amy J Johnson, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Nature Genetics|January 19, 2016
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemiaChristopher C Oakes, Marc Seifert, Yassen Assenov, et al.
Blood|March 23, 2021
Phase 2 study of ibrutinib in classic and variant hairy cell leukemiaKerry A Rogers, Leslie A Andritsos, Lai Wei, et al.
Blood|May 29, 2014
Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemiaRainer Claus, David M Lucas, Amy S Ruppert, et al.
Blood Advances|January 4, 2018
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinibCecelia R Miller, Amy S Ruppert, Nyla A Heerema, et al.
Nature Communications|November 4, 2021
Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemiaJanek S Walker, Zachary A Hing, Steven Sher, et al.
Pageof 19